Machine learning to identify treatment effect heterogeneity related to ICS and LAMA in the IMPACT trial - Vienna 2024

New aspects of lung function, inhalers and clinical management for asthma and COPD

Chair(s): Monbi Stefanova Chakma, Bernardino Alcazar Navarrete

Session type: Poster session

Machine learning to identify treatment effect heterogeneity related to ICS and LAMA in the IMPACT trial

Kenneth Verstraete

EVENTS HOME

Abstract

Previous presentation

Next presentation

Session content

Sustaining treatment for asthma and COPD patients while minimizing carbon footprint: effect of HFA-152a and HFA-134a on lung mucociliary clearance

Fran?ois Rony

Poster

Abstract

Machine learning to identify treatment effect heterogeneity related to ICS and LAMA in the IMPACT trial

Kenneth Verstraete

Abstract

Late Breaking Abstract - A novel macrolide, EP395, in patients with stable COPD: a RCT

Henrik Watz

Poster

Abstract

Late Breaking Abstract - A novel macrolide, EP395, in a LPS challenge in healthy volunteers

Jens Hohlfeld

Poster

Abstract

Demographic and asthma-related characteristics of asthmatics using pressurized metered dose inhalers and dry powder inhalers

Kurtulu? Aksu

Poster

Abstract

Self-Administration of Augmentation Therapy for Alpha 1-Antitrypsin Deficiency in Italy: a survey study.

Sara Lococo

Poster

Abstract

Inhaler Use in COPD Patients: A Cross-sectional Study, Critical Errors and Optimal Peak Inspiratory Flow measured with the InCheck Dial Device.

Sabri Jaffal

Poster

Abstract

Are we handling used metered dose inhaler canisters safely ? A call for action to address an environmental hazard.

Beena Thomas

Poster

Abstract

Pharmacogenetic Effects on Clusters of Lung Function Decline

Lies Lahousse

Poster

Abstract

Changes in determination of bronchodilator response in patients diagnosed with asthma

Martijn Cuijpers

Poster

Abstract

The carbon footprint of inhalers in secondary care: a cross-sectional analysis

Jasmin Abbott

Poster

Abstract

Real-world outcomes of Budesonide/Glycopyrronium/Formoterol therapy in COPD after 3 months; Interim analysis of the RECORD study

Henrik Watz

Poster

Abstract

Exacerbation reduction and improved quality of life in asthma with extrafine formulation single-inhaler triple therapy (efSITT): six-month results of the TriMaximize Study

Frederik Trinkmann

Poster

Abstract

Sustainable care: what are the characteristics of people with asthma who successfully switch to low carbon inhaler devices?

Grainne D'ancona

Poster

Abstract

The Cardiovascular Effects of Long-acting Bronchodilators Inhalers and Inhaled Corticosteroids purchases among Asthma and COPD patient

Dekel Shlomi

Poster

Abstract

A randomized, double-blind crossover study of change in post-dose lung function with a next generation propellant for metered dose inhalers in patients with asthma

Alan Bell

Poster

Abstract

Multidisciplinary approach to addressing sustainable inhaler prescribing across primary and secondary care in North Central London (NCL).

Kay Roy

Poster

Abstract

Impact of extrafine formulation single-inhaler triple therapy on asthma control and treatment adherence after six months of treatment in patients with asthma-TriMaximize study

Timm Greulich

Poster

Abstract

Improving clinician adherence to the green inhaler initiative: An audit of current practice

Aazaz Rehman

Poster

Abstract

Late Breaking Abstract - Do asthma patients prescribed a GLP1 have improved asthma and weight loss outcomes?

David Price

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}